The present study found that MK2206 did not completely reverse effects associated with MTA1 expression changes, indicating that pathways besides AKT/GSK3β/β-catenin signaling could be involved in MTA1-induceed EMT in NSCLC. This evidence concerns the gene GSK3B and non-small cell lung carcinoma.